Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Operating Grant: Industry-partnered Collaborative Research

University of Toronto

$126,664.00

Defining the structural basis for LXR beta antagonism

EF 2013-14

Résumé
Synthetic glucocorticoids (GCs) are among the most widely prescribed drugs in the world. Glucocorticoid drugs have profound anti-inflammatory and immunosuppressive properties that are critical for treating a wide variety of chronic conditions including rheumatoid arthritis and inflammatory bowel disease. Unfortunately, the development of major side-effects remains the key limitation for the long term therapeutic use of GCs. Common side effects that require either dosage adjustment or removal from therapy include: diabetes, high blood pressure, bone loss and muscle wasting. Our laboratory recently discovered that the protein receptor LXR beta (LXRb) is required for GC-induced diabetes and fatty liver but not for the beneficial GC-mediated anti-inflammatory effects. This discovery was made using genetically modified mice lacking the LXRb receptor. We have pursued this unexpected discovery by testing whether a small molecule that stops LXRb function could produce a similar result. Using an LXR antagonist developed by GlaxoSmithKline (GSK2033) we showed that co-treatment of this drug with a GC drug results in significantly reduced GC-induced side effects without altering the desired immunosuppressive effect. In this application, we plan to develop a second generation LXR antagonist that will have improved selectivity (LXRb > LXRa) and that will more easily enter the blood stream after oral dosing. The whole team will be involved at every stage to ensure that our project addresses the critical requirements for drug development today. Over the 2 year period, we will design, synthesize and evaluate a series of novel LXRb antagonists that will be useful in the treatment of GC-induced side effects including diabetes and fatty liver. In the future, these drugs will significantly improve the lives of Canadians that are currently prescribed GCs, by limiting the severity of the side effects that develop after long-term GC use.
Programme
Operating Grant: Industry-partnered Collaborative Research
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
292671
Name
Cummins Carolyn L
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
GlaxoSmithKline (Mississauga, Ontario); GlaxoSmithKline (Mississauga, Ontario)
Instname2
Nutrition, Metabolism and Diabetes
Theme2
Biomedical
Prcname2
Industry Partnered Collaborative Research
Projecttitle
Defining the structural basis for LXR beta antagonism
Programtype2
Operating Grants
Orgnameinp2
University of Toronto
Cihramount2
$126,664
Cihrequipment2
$0
Programname2
Operating Grant: Industry-partnered Collaborative Research
Keyworddelim
Co-Transfection Assays; Dexamethasone; Ligand Binding Assays; Liver X Receptor; Nuclear Receptor; P450 Metabolism; Physicochemical Properties; Primary Hepatocytes; Structure Based Drug Design; Synthetic Chemistry
Abstract
Synthetic glucocorticoids (GCs) are among the most widely prescribed drugs in the world. Glucocorticoid drugs have profound anti-inflammatory and immunosuppressive properties that are critical for treating a wide variety of chronic conditions including rheumatoid arthritis and inflammatory bowel disease. Unfortunately, the development of major side-effects remains the key limitation for the long term therapeutic use of GCs. Common side effects that require either dosage adjustment or removal from therapy include: diabetes, high blood pressure, bone loss and muscle wasting. Our laboratory recently discovered that the protein receptor LXR beta (LXRb) is required for GC-induced diabetes and fatty liver but not for the beneficial GC-mediated anti-inflammatory effects. This discovery was made using genetically modified mice lacking the LXRb receptor. We have pursued this unexpected discovery by testing whether a small molecule that stops LXRb function could produce a similar result. Using an LXR antagonist developed by GlaxoSmithKline (GSK2033) we showed that co-treatment of this drug with a GC drug results in significantly reduced GC-induced side effects without altering the desired immunosuppressive effect. In this application, we plan to develop a second generation LXR antagonist that will have improved selectivity (LXRb > LXRa) and that will more easily enter the blood stream after oral dosing. The whole team will be involved at every stage to ensure that our project addresses the critical requirements for drug development today. Over the 2 year period, we will design, synthesize and evaluate a series of novel LXRb antagonists that will be useful in the treatment of GC-induced side effects including diabetes and fatty liver. In the future, these drugs will significantly improve the lives of Canadians that are currently prescribed GCs, by limiting the severity of the side effects that develop after long-term GC use.
Competitiondate
201309
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Cummins, Carolyn L
Approvedterm
2 ans 0 mois
Cihrcontribution2
Knowledge Translation Branch~ $126,664~ $0~